Partnering with
MOGRIFY
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical. We are particularly interested in speaking with those with interest in immuno-oncology, ophthalmology as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development and co-development partnerships, as well as the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application.
Current
PARTNERS
Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering.
MRC Laboratory for Molecular Biology
The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, they provide knowledge needed to solve key problems in human health.
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
Duke-NUS Medical School
Duke-NUS Medical School is a research powerhouse and our distinguished scientists are transforming the way we understand, diagnose and treat diseases. Our founder, Assistant Professor, Owen Rackham, and his group at the School focus on what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. Developing methods that leverage the large volume of gene expression, epigenetic and interaction data that is being generated to develop biological hypotheses about how certain perturbations can influence cell fate.
Monash University
The Polo Laboratory, a part of the Monash Biomedicine Discovery Institute at Monash University, focuses on the transcriptional and epigenetic mechanisms that govern cell identity, in particular, pluripotency and the reprogramming of somatic cells into induced pluripotent stem (iPS) cells.
Our
PIPELINE
| AREA | Sample Acquisition | Bioinformatics | In vitro PoC | In vivo PoC | IND | Clinical | Marketing |
|---|---|---|---|---|---|---|---|
| Immunotherapy (Oncology) | mogrify | mogrify | mogrify | mogrify | partner | partner | |
| Ophthalmology (Retinal) | mogrify | mogrify | mogrify | partner | partner | ||
| Collaborations (Pulmonary, Metabolic & Others) | mogrify | mogrify | mogrify | partner | partner | partner | partner |
| mogrify | Mogrify Progress | partner | Expect to Partner |
Upcoming
Events & Conferences
The ISSCR Annual Meeting gathers the world’s leading scientists, clinicians, business leaders, ethicists, and educators from more than 65 countries. Together, we represent the full spectrum of stem cell science and regenerative medicine. Discovery, new business, careers, advocacy, and relationships start here.
Harnessing Disruptive CAR & TCR Based Cell Technologies to Supercharge Safe, Effective & Globally Accessible Cell Immunotherapies in Oncology & Beyond
The Sixth European Congress of Immunology (6th ECI 2021) that will be held virtually from September 1-4, 2021 and will cover all fields of basic and applied immunology, ranging from innate to adaptive to omics aided big data mining of forward genetics and vaccination as well as mechanistic regulation of memory generation and tissue specific instruction of T- and B- cell differentiation.
Multiomics to Mechanisms: Challenges in Data Integration is the third in series of EMBL|EMBO symposia focusing on challenges and opportunities in data integration, with the goal to provide a platform for discussing and presenting strategies for multiomics data integration that go beyond descriptive analyses and aim towards mechanistic, biological interpretation.
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
The 2021 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.
LSX’s Investival Showcase connects life science corporates to global capital and partners in an international showcase of early, growth stage and public life science and health technology companies across Europe and beyond.